3 results
Approved WMORecruiting
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…
Approved WMORecruiting
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.
Approved WMORecruiting
Primary objective:To assess the (short-term) safety of the WEAKID nighttime system in a limited number (n=12) of patients and sessions (6 sessions per patient).Secondary objectives1. To evaluate the incidence of AE*s and DD*s other than SADE*s and…